Recently, Hongxing Erke (Xiamen) Investment Management Co., Ltd. (referred to as Hongxing Erke Investment) held a brand launch and product release conference for its subsidiary Duo Ying (Xiamen) Biotechnology Co., Ltd. (referred to as Duo Ying Biotech) in Xiamen. During the event, Hongxing Erke launched a skincare brand called Emputone, which focuses on recombinant collagen.
It is reported that Hongxing Erke is a Chinese sportswear company. The company has over 7,000 stores worldwide and its products are sold in countries and regions such as Europe, Southeast Asia, the Middle East, North and South America, and Africa. It holds trademark rights in more than 100 countries globally, and its brand value has exceeded 21.9 billion yuan ($3.06 billion).
Not long ago, L’Oréal Paris added “recombinant collagen” to its products. According to Frost & Sullivan’s estimates, by 2025, collagen is projected to surpass hyaluronic acid and become the largest raw material component in skincare products. CHAILEEDO understands that Hongxing Erke has been actively expanding its presence in the field of recombinant collagen in recent years. During this event, they also unveiled a range of recombinant collagen products developed in collaboration with Polygenomix, including recombinant Type III human collagen solution, patches, and repair gels for various applications.
Public information indicates that Duo Ying Biotech, a subsidiary of Hongxing Erke Investment, is a high-tech company specializing in synthetic biology. It integrates cosmetics research and development, production, and sales and owns independent brands called “Duo Ying” and “Emputone”. These brands cover areas such as functional skincare and post-medical aesthetic care in the beauty industry.
